Medexus PharmaceuticalsMEDXF +3.96%60 Gross Margin % is 53.84% as of Mar. 2026, which is 0% above its 10-year median of 53.76. GuruFocus rates MEDXF with a GF Score™ of 60/100 and a GF Value™ of $1.32 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 937 Drug Manufacturers companies, Medexus Pharmaceuticals ranks better than 60.62% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medexus Pharmaceuticals had a gross margin of 53.84% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medexus Pharmaceuticals Gross Margin % Related Terms
Medexus Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medexus Pharmaceuticals (MEDXF) has a Gross Margin % of 53.84% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Medexus Pharmaceuticals and its competitors. This is near median its historical median of 53.76. Over the past decade, Medexus Pharmaceuticals' Gross Margin % has ranged from 49.45 to 59.68. According to the industry distribution chart, Medexus Pharmaceuticals ranks #369 out of 937 companies in the Drug Manufacturers industry, placing it in the top 39.4%.
Is Medexus Pharmaceuticals' Gross Margin % too high?
Medexus Pharmaceuticals' current Gross Margin % of 53.84% is near median its 10-year median of 53.76. Over the past 10 years, this metric has ranged from a low of 49.45 to a high of 59.68. The Drug Manufacturers industry median Gross Margin % is 48.46. Medexus Pharmaceuticals' value of 53.84% is 11.1% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #369 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medexus Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #369 out of 937 companies for Gross Margin %. This puts Medexus Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 48.46. Medexus Pharmaceuticals' value of 53.84% is 11.1% above this benchmark. Historically, Medexus Pharmaceuticals' own Gross Margin % has ranged from 49.45 to 59.68 over the past decade. While the company's 10-year median is 53.76 vs. the industry median of 48.46, Medexus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current Gross Margin % of 53.84% is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current Gross Margin % is 53.84%, which is near median its own 10-year median of 53.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.62 — trading 174.2% above its estimated fair value. The current Gross Margin % is 53.84%, which is near median its 10-year median of 53.76 and 11.1% above the Drug Manufacturers industry median of 48.46. Medexus Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current Gross Margin % is 53.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.62 is trading 174.2% above its estimated GF Value™ of $1.32.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEDXF:
Gross Margin %: 53.84% (near median its 10-year median of 53.76)
GF Value™: $1.32 vs. price of $3.62 (174.2% above fair value)
Industry Position: 11.1% above the Drug Manufacturers median (#369 of 937)
No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
60GF Score
Get the complete analysis for MEDXF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDXF has been successfully added to your 
